| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 12.05 | 2.5% | 18.3% |
| Total Income | 12.05 | 2.5% | 18.3% |
| Expenditure | 11.42 | 9.6% | 8.7% |
| PBT | 0.26 | 132.1% | 236.8% |
| Net Profit | 0.25 | 130.9% | 219.1% |
| OPM | 5.21% | 12.56pp | 8.27pp |
| NPM | 2.10% | 8.96pp | 4.13pp |
| EPS | 0.01 | 150.0% |
KORU Medical Announces Q2 2026 Results, Revenue Up 18% to $12.0 Million
06 Aug 2026 · 6 Aug, 1:43 am
Summary
KORU Medical Systems reported strong second quarter 2026 results, with net revenues increasing 18.2% year-over-year to $12.0 million. Gross profit rose 21.2% to $7.8 million, and gross margin improved to 65.1%. Net income turned positive at $0.25 million, a significant improvement from a net loss in the prior year period. The company also announced a strategic acquisition of connected monitoring technology and a shift in its U.S. oncology market entry strategy. Full year 2026 guidance was updated to reflect revenues between $47.5 - $48.5 million and gross margins of 62% - 64%.
Key Highlights
- 1
Net revenues grew 18% over the prior year period to $12.0 million for the second quarter of 2026.
- 2
Gross profit grew 20% over the prior year period to $7.8 million, with gross margin of 65.1%.
- 3
Net income improved 222% over the prior year period to $0.25 million for the second quarter of 2026.
- 4
The company acquired a connected monitoring technology asset, representing a strategic investment to potentially enhance the KORU platform.
- 5
KORU Medical is strategically shifting its U.S. oncology market entry to focus on alternative higher volume molecules and withdrawing its 510(k) application for the FreedomEDGE® with Phesgo® in the U.S.
- 6
A multi-year supply agreement was entered into to support operational strategy, product assurance, and long-term gross margin expansion.
- 7
Full year 2026 guidance was refined to include revenue of $47.5 - $48.5 million, gross margin of 62% - 64%, positive adjusted EBITDA, and a year-end cash balance of greater than $7.5 million.
Management Comments
Adam Kalbermatten
We delivered record revenue, improved gross margins and generated positive net income for the quarter, all of which demonstrate our ability to drive durable and profitable growth in the subcutaneous drug delivery market. We also acquired a technology asset, representing a strategic investment in connected monitoring potential to further enhance the patient experience and differentiate KORU’s value proposition to our partners. Looking ahead for the remainder of 2026, we expect our international core growth to moderate as we navigate regional launch dynamics in specific European markets converting to pre-filled syringes. We remain confident in the size of our international opportunity and view capturing this business only as a matter of timing. Additionally, we have withdrawn our Phesgo® 510(k) application and shifted our U.S. oncology strategy to focus on alternative molecules with higher infusion volumes. Overall, we are pleased with our performance in the quarter and are focused on executing our growth strategy with operational discipline to drive durable value creation.
Informational and educational content only. Not investment advice.